Search

everythinglearnresearchcommunity

for

Search:↓

The user is using caffeine shampoo with baicapil, microneedling, massage, and procapil lotion for hair loss. Replies suggest the user is balding and recommend finasteride.

A user shared their 2-month progress on hair regrowth using oral minoxidil, oral finasteride, and topical minoxidil with pyrilutamide. They reported seeing tiny hairs growing and no side effects from finasteride so far.

2-deoxy-D-ribose is being explored as a hair loss treatment but is not proven effective in humans and may be costly and inconvenient. Minoxidil remains the most effective treatment.

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.

After 2 months of using minoxidil and finasteride twice daily, along with ketoconazole shampoo 2-3 times a week, progress in hair condition is shown. The user shares pictures to document the changes.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

Starting with 5 mg of oral minoxidil for faster initial results, then reducing to 2.5 mg to maintain progress. The user seeks opinions on this approach.

A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

A user started taking 2.5mg oral Minoxidil (OM) and 1mg Finasteride after using topical Finasteride, Minoxidil, and Tretinoin for 2.5 months. They are considering increasing the OM dose before an upcoming hair transplant to improve its success.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

Latanoprost/bimatoprost's effectiveness in hair loss treatment is discussed, with its potential to convert vellus hairs to terminal hairs. It works differently from minoxidil and finasteride, and may be best for hairline application, but is not a replacement for them due to price and mechanism.

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

A user maintains NW2 hair with 1mg finasteride, 2.5mg oral minoxidil, and 5% topical minoxidil twice daily, along with ketoconazole shampoo and derma stamping. They seek advice on more aggressive treatments to achieve NW1.

RU58841's potential toxicity to cats is uncertain, similar to minoxidil. Caution is advised to prevent accidental exposure to pets.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

A 33-year-old male is documenting his hair regrowth progress using minoxidil, red light therapy, copper peptides, and micro-needling, with noticeable improvement in hair thickness and coverage. He plans to add a topical finasteride/minoxidil spray and aims for a shadow on his scalp rather than a full head of hair.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

A 17-year-old shared progress pictures after using RU58841 and Minoxidil for 2 months, showing significant hair regrowth. Another user commented on the impressive results achieved in a short time.

A 22-year-old shared his 2-month progress using oral Minoxidil (3mg) and Finasteride (1.1mg) for hair regrowth, showing noticeable improvement despite initial side effects like increased heart rate and headaches. Users discussed the effectiveness, side effects, and expectations of these treatments, with some expressing skepticism about the rapid results.

Microneedling combined with latanoprost may convert vellus hairs to transitional or terminal hairs. The user suggests using oral minoxidil to increase vellus hair, then applying a high concentration of latanoprost with microneedling for conversion.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

User sshamu's progress pictures of 4 months using minoxidil foam and 1MM dermarolling for hair loss, which resulted in impressive results. There is also discussion about how often to use the treatments, as well as potential side effects of finasteride.

Botox injections increase hair density in patients with androgenetic alopecia. Combining Botox with finasteride yields even better results.